- Zelira Therapeutics (ZLD) has launched its Hope products in Australia after receiving Therapeutic Goods Administration (TGA) approval
- The two proprietary cannabinoid formulations, Hope 1 and Hope 2, were developed to support the needs of patients with Autism Spectrum Disorder
- The Hope products were launched in the U.S. state of Pennsylvania last year and Louisiana in August this year
- In August this year, the products were also launched in Louisiana, in partnership with Advanced Biomedics
- The company has now launched five products in 2020
- Following today’s announcement, Zelia shares are up 8.86 percent, priced at 8.6 cents at 10:48 am AEDT
